Login details for the virtual meeting portal have been sent
You should have now received your login details for the virtual meeting portal, if you have not received your login details please check your junk folder and then contact Expert Events on 07 3848 2100.
We invite you to attend the ASCEPT-APSA Joint Virtual Scientific Meeting.
The ASCEPT-APSA 2020 Joint Scientific Meeting will be held as a virtual event from Tuesday 24 to Thursday 26 November 2020. The presentations are likely to run from 12.30pm to approx 5.00pm (AEST) on Tuesday and Wednesday with an earlier finish on Thursday.
The virtual meeting program will include:
- keynote presentations
- society award presentations
- APSA Medal
- APSA Emerging Leader Award
- ASCEPT Lecture
- CERTARA Young Investigator Awards
- ASCEPT Gillian Shenfield Early Educator Award
- ASCEPT Early Achievement Award for Women
- ASCEPT Garth McQueen Prize
- APSA student prizes
- ASCEPT student prizes
- symposia
- short oral presentations from abstract submission
- ePoster presentations from abstract submission
- networking opportunities
- group discussions.
This virtual event will allow students and members to continue to present their research and discuss quality science. The event will involve sessions with questions from the audience and group discussions so that participants can engage and network with their colleagues.
Thank you for your continued interest and your support of both ASCEPT and APSA.
ASCEPT-APSA 2020 Organising Committee
| Dr Dan Wright ASCEPT Co-chair | Dr Jonathan Penm APSA Co-chair |
 |  |
Who should attend:
The conference is open to members and non-members from related disciplines, and is relevant for:
o Scientists from academia and industry who are involved in drug discovery, drug formulation and drug delivery research and development
o Researchers in the fields of neuropharmacology, cardiovascular pharmacology, respiratory and inflammatory disease pharmacology, urogenital and gastrointestinal pharmacology, toxicology, pharmacogenomics and pharmacoepidemiology.
o Regulatory and clinical scientists involved in bioavailability and bioequivalence study design and assessment, preparation and review of regulatory dossiers
o Researchers and clinicians in the clinical and practice areas of pharmacy
o Academics and researchers and with an interest in pharmacy education
o Government agencies involved in chemical safety assessment and registration
o Medical practitioners such as clinical pharmacologists, clinical toxicologists, cardiologists and general physicians.
o Students and postdoctoral fellows from all areas of pharmacology, toxicology, pharmacy practice, pharmacy education and pharmaceutical sciences.